Arvind Remedies Ltd
Arvind Remedies (ARL) engages in the drugs and pharmaceuticals business of India that manufactures capsules, liquids, ointments, tablets Syrup, Cream & Powders as well as Ayurvedic products at Kancheepuram in Tamilnadu.
- Market Cap ₹ 31.7 Cr.
- Current Price ₹ 4.70
- High / Low ₹ /
- Stock P/E 0.54
- Book Value ₹ 41.6
- Dividend Yield 0.00 %
- ROCE 20.2 %
- ROE 24.3 %
- Face Value ₹ 10.0
Pros
- Stock is trading at 0.11 times its book value
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | |
|---|---|---|---|---|
| 363 | 468 | 706 | 963 | |
| 321 | 395 | 566 | 781 | |
| Operating Profit | 41 | 72 | 140 | 181 |
| OPM % | 11% | 15% | 20% | 19% |
| 0 | 1 | 1 | 1 | |
| Interest | 16 | 29 | 60 | 79 |
| Depreciation | 2 | 4 | 13 | 14 |
| Profit before tax | 23 | 40 | 68 | 89 |
| Tax % | 26% | 46% | 34% | 32% |
| 17 | 22 | 45 | 60 | |
| EPS in Rs | 0.35 | 0.43 | 0.90 | 8.59 |
| Dividend Payout % | 20% | 16% | 11% | 9% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 38% |
| TTM: | 36% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 51% |
| TTM: | 35% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 1% |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 23% |
| Last Year: | 24% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | |
|---|---|---|---|---|
| Equity Capital | 48 | 48 | 48 | 68 |
| Reserves | 73 | 96 | 150 | 215 |
| 187 | 371 | 529 | 641 | |
| 61 | 112 | 139 | 199 | |
| Total Liabilities | 370 | 628 | 867 | 1,123 |
| 45 | 249 | 258 | 357 | |
| CWIP | 19 | 49 | 37 | 67 |
| Investments | 0 | 0 | 0 | 0 |
| 306 | 330 | 572 | 700 | |
| Total Assets | 370 | 628 | 867 | 1,123 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | |
|---|---|---|---|---|
| 12 | 6 | 13 | -65 | |
| -62 | -157 | -122 | -25 | |
| 55 | 153 | 111 | 71 | |
| Net Cash Flow | 6 | 2 | 2 | -18 |
| Free Cash Flow | -50 | -150 | -109 | -90 |
| CFO/OP | 46% | 17% | 19% | -32% |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | |
|---|---|---|---|---|
| Debtor Days | 135 | 146 | 134 | 133 |
| Inventory Days | 72 | 88 | 87 | 101 |
| Days Payable | 52 | 48 | 50 | 49 |
| Cash Conversion Cycle | 156 | 186 | 171 | 185 |
| Working Capital Days | 162 | 168 | 173 | 202 |
| ROCE % | 17% | 21% | 20% |
Insights
In beta| Mar 2014 | Jun 2015 | |
|---|---|---|
| Electricity Consumption Units |
|
|
| Number of Manufacturing Facilities Number |
||
| Personnel Cost INR Lakhs |
||
| R&D Expenditure as % of Turnover % |
||
| Number of Shareholders Number |
||
| R&D Expenditure (Percentage of Turnover) % ・Standalone data |
||
Extracted by Screener AI